Safety and Bioequivalence of Pimecrolimus Cream 1% and Elidel R in Treatment of Mild to Moderate Atopic Dermatitis
Status:
Completed
Trial end date:
2017-06-01
Target enrollment:
Participant gender:
Summary
A phase 3, double-blind, randomized, parallel-group, placebo-controlled, multicenter study to
evaluate the safety and bioequivalence of Par Pharmaceutical Inc.'s Pimecrolimus Cream, 1%
and Reference Listed Elidel® (Pimecrolimus Cream, 1%). The study compares both active
treatments to a placebo control in the treatment of mild to moderate atopic dermatitis.